Multiple antigen-presenting system (MAPS) to induce comprehensive B-and T-cell immunity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 33, 2013, Pages 13564-13569

  Zhang, Fan ^a   Lu, Ying Jie ^a   Malley, Richard ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; POLYSACCHARIDE; PROTEIN; SUBUNIT VACCINE;

ANTIGEN PRESENTATION; ANTIGENICITY; ARTICLE; CELLULAR IMMUNITY; HUMORAL IMMUNITY; IMMUNIZATION; MOLECULAR SIZE; MOUSE; MULTIPLE ANTIGEN PRESENTING SYSTEM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHI; STREPTOCOCCUS PNEUMONIA; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; DRUG DESIGN; HUMANS; IMMUNITY, CELLULAR; MACROMOLECULAR SUBSTANCES; MYCOBACTERIUM TUBERCULOSIS; SALMONELLA TYPHI; STREPTOCOCCUS PNEUMONIAE; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES, ACELLULAR;

EID: 84882413295     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1307228110     Document Type: Article

References (37)

1. Plotkin SA, Plotkin SL (2011) The development of vaccines: How the past led to the future. Nat Rev Microbiol 9(12):889-893.
2. Kolls JK, Khader SA (2010) The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev 21(6):443-448.
3. Cho JS, et al. (2010) IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 120(5):1762-1773.
4. Khader SA, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8(4):369-377.
5. Khader SA, et al. (2005) IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 175(2): 788-795.
6. Aujla SJ, Dubin PJ, Kolls JK (2007) Th17 cells and mucosal host defense. Semin Immunol 19(6):377-382.
7. Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378(9807):1962-1973.
8. Queenan AM, Cassiday PK, Evangelista A (2013) Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 368(6):583-584.
9. Lipsitch M, O'Hagan JJ (2007) Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface 4(16):787-802.
10. Helppolainen SH, et al. (2007) Rhizavidin from Rhizobium etli: The first natural dimer in the avidin protein family. Biochem J 405(3):397-405.
11. Janeway CA, Travers P, Walport M, Shlomchik MJ (2001) Immunobiology (Garland, New York), 5th Ed.
12. Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 82(5):488-496.
13. Ottenhoff TH, Kaufmann SH (2012) Vaccines against tuberculosis: Where are we and where do we need to go? PLoS Pathog 8(5):e1002607.
14. Berry AM, Paton JC (1996) Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun 64(12): 5255-5262.
15. Berry AM, Ogunniyi AD, Miller DC, Paton JC (1999) Comparative virulence of Streptococcus pneumoniae strains with insertion-duplication, point, and deletion mutations in the pneumolysin gene. Infect Immun 67(2):981-985.
16. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone, I: Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136(7):2348-2357.
17. Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25:821-852.
18. Kwok SK, et al. (2012) TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren's syndrome. Arthritis Res Ther 14(2):R64.
19. Nyirenda MH, et al. (2011) TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol 187(5):2278-2290.
20. Austrian R (1986) Some aspects of the pneumococcal carrier state. J Antimicrob Chemother 18(Suppl A):35-45.
21. Moffitt KL, Malley R (2011) Next-eneration pneumococcal vaccines. Curr Opin Immunol 23(3):407-413.
22. Malley R (2010) Antibody and cell-mediated immunity to Streptococcus pneumoniae: Implications for vaccine development. J Mol Med (Berl) 88(2):135-142.
23. Malley R, et al. (2006) Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 74(4):2187-2195.
24. McDaniel LS, Waltman WD, 2nd, Gray B, Briles DE (1987) A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid. Microb Pathog 3(4):249-260.
25. Moffitt KL, Malley R, Lu YJ (2012) Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine. PLoS ONE 7(8): e43445.
26. Whaley MJ, et al. (2010) Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine 28(18):3071-3075.
27. Lu YJ, et al. (2010) GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 28(47):7468-7475.
28. Gangarosa EJ, et al. (1998) Impact of anti-vaccine movements on pertussis control: The untold story. Lancet 351(9099):356-361.
29. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30(1):23-32.
30. Ramon G (1924) Diphtheria toxin and anatoxin. Ann Inst Pasteur (Paris) 38:1-10.
31. Xiang SD, et al. (2006) Pathogen recognition and development of particulate vaccines: does size matter? Methods 40(1):1-9.
32. Casella CR, Mitchell TC (2008) Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65(20):3231-3240.
33. Blander JM, Medzhitov R (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085):808-812.
34. Avci FY, Li X, Tsuji M, Kasper DL (2011) A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 17(12):1602-1609.
35. Anderson P, Insel RA (1981) A polysaccharide-protein complex from Haemophilus influenzae type b, I: Activity in weanling rabbits and human T lymphocytes. J Infect Dis 144(6):509-520.
36. Pichichero ME, Porcelli S, Treanor J, Anderson P (1998) Serum antibody responses of weanling mice and two-year-old children to pneumococcal-type 6A-protein conjugate vaccines of differing saccharide chain lengths. Vaccine 16(1):83-91.
37. Anderson P, Pichichero M, Insel R, Farsad P, Santosham M (1985) Capsular antigens noncovalently or covalently associated with protein as vaccines to Haemophilus influenzae type b: Comparison in two-year-old children. J Infect Dis 152(3):634-636.